

# Expanding Presence In State

## Piramal Group to inject ₹500cr in 3 years in T

TIMES NEWS NETWORK

Hyderabad: In a booster shot for Telangana's pharma sector, Piramal Group is drawing up plans to invest ₹500 crore in expanding its pharma presence in the state over the next three years.



Piramal Group company Piramal Pharma, which already has manufacturing facilities at Digwal in Medak district, will be enhancing its production capacities in the state by setting up new manufacturing blocks and warehousing facilities, among others.

This commitment was given by Piramal Group chairman Ajay Piramal to state industries and IT minister K Taraka Rama Rao (KTR) at the ongoing World Economic Forum at Davos following a series of deliberations, KTR's office said.

The expansion includes enhancing the existing capacities of Piramal Pharma in the state as well as setting up greenfield facilities at the upcoming Pharma City on Hyderabad's outskirts.

The proposed expansion is slated to create 500-600 additional jobs by FY23. At present, Piramal group employs close to 1,400 people, including full-time and contract staff, at its existing facility in Hyderabad.

According to the Telangana government, Piramal Pharma is not only keen on adding capacities through

acquisitions in and around Hyderabad to support its API manufacturing operations here but also plans to shift its capacities from other states to a new location in Hyderabad to take advantage of the ease of doing business in the state.

While Piramal Pharma will be expanding its presence at the existing site at Digwal, it is also considering the upcoming Pharma City for its future greenfield project, industries & IT principal secretary Jayesh Ranjan told TOI from Davos.

The Piramal leadership team will also be visiting the new site early next month, it is learnt.

Piramal Pharma's existing facility at Digwal, which is located on a 100-acre campus, is a cGMP active pharmaceutical ingredients (API) manufacturing facility approved by various regulatory agencies across the globe, including US and European drug regulators.

The dedicated multi-purpose plant is engaged in custom manufacturing and development for late phase APIs and advanced intermediates.

It comprises three units with multiple production blocks having a total reactor volume exceeding 1000 KL.

The Digwal facility is a fully functional zero discharge facility.

It manufactures close to 2000 MT of finished goods, including APIs like Isoflurane, Diltiazem, Mebeverine, Ketoconazole that are exported to over 60 countries.